Search Result
Results for "
capsid inhibitor
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13750
-
Ebselen
Maximum Cited Publications
24 Publications Verification
SPI-1005; PZ-51; CCG-39161
|
Calcium Channel
Virus Protease
HIV
Phosphatase
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Ebselen (SPI-1005), a glutathione peroxidase mimetic, is a potent voltage-dependent calcium channel (VDCC) blocker . Ebselen potently inhibits M pro (IC50=0.67 μM) and COVID-19 virus (EC50=4.67 μM) .Ebselen is an inhibitor of HIV-1 capsid CTD dimerization. Ebselen, an organoselenium compound, can permeate the blood-brain barrier and has anti-inflammatory, antioxidant and anticancer activity .
|
-
-
- HY-111964
-
|
GS-6207
|
HIV
|
Infection
|
|
Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
|
-
-
- HY-B1464
-
|
|
Environmental Pollutants
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
|
Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products .
|
-
-
- HY-19952
-
|
VP 63843; Win 63843
|
Enterovirus
|
Infection
|
|
Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research .
|
-
-
- HY-109168
-
|
JNJ-6379; JNJ-56136379
|
HBV
DNA/RNA Synthesis
|
Infection
|
|
Bersacapavir (JNJ-6379) is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .
|
-
-
- HY-104074
-
|
SCH-48973; V-073
|
Enterovirus
|
Infection
|
|
Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
|
-
-
- HY-125474
-
|
|
Environmental Pollutants
HIV
HSV
|
Infection
Cancer
|
|
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .
|
-
-
- HY-W019806
-
|
LNFP I
|
Endogenous Metabolite
CDK
Reactive Oxygen Species (ROS)
Apoptosis
Enterovirus
Bacterial
|
Infection
Inflammation/Immunology
|
|
Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .
|
-
-
- HY-120072
-
|
PF-74
|
HIV
|
Infection
|
|
PF-3450074 (PF-74) is a specifical inhibitor of HIV-1 capsid protein (CA) and displays a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). PF-3450074 (PF-74) acts at an early stage of HIV-1 infection, inhibits viral replication by directly competing with the binding of CPSF6 and NUP153, and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle . CPSF6: nuclear host factors cleavage and polyadenylation specific factor 6; NUP153: nucleoporin 153.
|
-
-
- HY-148348
-
|
|
HBV
|
Infection
|
|
AB-836 is an orally active HBV capsid inhibitor. AB-836 inhibits viral replication by interacting with HBV core protein. AB-836 can be used in research related to chronic hepatitis B .
|
-
-
- HY-N2036
-
|
|
TNF Receptor
Enterovirus
Bacterial
|
Infection
|
|
Mosloflavone is a flavonoid isolated from Scutellaria baicalensis Georgi with ?anti-EV71 activity. Mosloflavone? inhibits VP2 virus replication and protein expression during the initial stage of virus infection and inhibits viral VP2 capsid protein synthesis. Mosloflavone is a promising biocide and inhibits P. aeruginosa virulence and biofilm formation.
|
-
-
- HY-N0842
-
|
PA-457; MPC-4326; YK FH312
|
Virus Protease
|
Infection
|
|
Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies .
|
-
-
- HY-177022
-
|
|
HBV
|
Infection
|
|
ALG-001075, a capsid assembly modulator (CAM), is an orally active HBV inhibitor. ALG-001075 effectively blocks not only HBV DNA production but also extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. ALG-001075 shows pronounced reductions of circulating HBV DNA in the AAV-HBV mouse model. ALG-001075 can be used for the study of Chronic hepatitis B (CHB) .
|
-
-
- HY-111964A
-
|
GS-6207 sodium
|
HIV
|
Infection
|
|
Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
|
-
-
- HY-19476
-
|
|
Virus Protease
|
Infection
|
|
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus .
|
-
-
- HY-159828
-
|
VH-499; VH4011499
|
HIV
|
Infection
|
|
Dezecapavir (VH-499) is a HIV-1 capsid protein inhibitor. Dezecapavir exhibits picomolar-level antiviral activity against a variety of HIV-1 laboratory strains and clinical isolates in vitro. Dezecapavir inhibits the early and late stages of the HIV-1 life cycle, blocking nuclear import, reverse transcript production, virion assembly, maturation, and post-nuclear import/pre-integration replication processes. Dezecapavir can be used in studies related to HIV-1 infection .
|
-
-
- HY-124614
-
GLP-26
2 Publications Verification
|
HBV
|
Infection
|
|
GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC50=3 nM), and reduces cccDNA by >90% at 1 μM.
GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools . GLP-26 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-W012017
-
|
|
Enterovirus
|
Infection
|
|
2-Hydroxytetradecanoic acid is a hydroxy fatty acid that inhibits cleavage between the enterovirus capsid proteins VP4 and VP2. 2-Hydroxytetradecanoic Acid has anti-virus activity .
|
-
-
- HY-112142
-
AB-423
3 Publications Verification
(R)-DVR-23
|
HBV
|
Infection
|
|
AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells.
|
-
-
- HY-124594
-
|
GS-6207 analog
|
HIV
|
Infection
|
|
CA inhibitor 1 (GS-6207 analog) is a potent HIV capsid inhibitor for HIV inhibition . CA inhibitor 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-103078
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
|
-
-
- HY-111233
-
|
WIN-51711
|
Enterovirus
|
Infection
|
|
Disoxaril (WIN-51711) is an antivirus agent with activity against poliovirus types 1 and 2. Disoxaril inserts into the hydrophobic interior of virus capsid protein VP1 to stabilize virion conformation, inhibits poliovirus uncoating, and prevents viral RNA release and synthesis. Disoxaril can be used for the research of poliovirus infection .
|
-
-
- HY-121663
-
|
|
Dengue Virus
|
Infection
|
|
ST-148 is a novel small molecule compound that has potent inhibitory effects against all four dengue virus serotypes. In the nonlethal AG129 mouse dengue virus infection model, ST-148 significantly reduced viremia and viral load in vital organs and tended to reduce plasma cytokine levels. Compound resistance was associated with the dengue virus capsid (C) gene, and the direct interaction of ST-148 with the C protein was presumed to be achieved through the protein's built-in fluorescence change in the presence of the compound. Therefore, ST-148 appears to interact with the dengue virus C protein and inhibit one or more unique steps of the viral replication cycle.
|
-
-
- HY-177097
-
|
|
HIV
|
Infection
|
|
Lenacapavir pacfosacil (Example 44) is a viral capsid and nucleocapsid inhibitor. Lenacapavir pacfosacil has antiviral effects. Lenacapavir pacfosacil can be used for research of Retroviridae infection, including an HIV infection .
|
-
-
- HY-146204
-
|
|
HIV
|
Infection
|
|
HIV-1 capsid inhibitor 1 is a potent HIV-1 Capsid inhibitor with an EC50 value of 3.13 µM. HIV-1 capsid inhibitor 1 shows antiviral activities .
|
-
-
- HY-103078A
-
|
|
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 sodium is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 sodium disrupts capsid function and reduces polymerization levels. I-XW-053 sodium effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 sodium can be widely used in studies related to HIV-1 infection .
|
-
-
- HY-178741
-
|
|
HIV
|
Infection
|
|
KFA-027 is a HIV-1 inhibitor, with an IC50 of 0.398 nM. KFA-027 inhibits capsid-dependent early steps (reverse transcription, nuclear import, integration) and late-stage aberrant capsid assembly in the HIV-1 replication cycle. KFA-027 can be used for the study of multidrug-resistant HIV-1 infections .
|
-
-
- HY-P10805
-
|
|
HIV
|
Infection
|
|
Capsid assembly inhibitor is a 12-mer peptide that binds the capsid (CA) domain of Gag and inhibits assembly of immature- and mature-like HIV-1 capsid particles in vitro .
|
-
-
- HY-123211
-
|
|
HSV
|
Infection
|
|
WAY-150138 inhibits replication of herpes simplex virus type 1 (HSV-1) that acts by preventing the incorporation of DNA-packaging proteins into capsids as they are assembled
|
-
-
- HY-145850
-
|
|
Enterovirus
|
Infection
|
|
EV-A71-IN-1 is a human enterovirus A71 (EV-A71) capsid protein inhibitor with an EC50 of 0.27 μM against EV-A71. EV-A71-IN-1 is a capsid binder that blocks the interaction between the viral VP1 and the host receptor hSCARB2. EV-A71-IN-1 inhibits a series of different human enteroviruses without significant cytotoxicity (CC50>56.2 μM) .
|
-
-
- HY-177638
-
|
|
HSV
|
Infection
|
|
ISIS 1082 is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro
|
-
-
- HY-148768
-
|
|
HBV
|
Inflammation/Immunology
|
|
AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research .
|
-
-
- HY-117137
-
|
|
CMV
|
Infection
|
|
GW 275175X is an inhibitor of the terminase complex involved in cleavage and packaging of the unit length DNA into the capsids. GW 275175X exhibits long plasma half-life. GW 275175X is a BDCRB derivative. GW 275175X exhibits anti-HCMV activity through inhibiting maturation of viral DNA .
|
-
-
- HY-120764
-
|
|
HIV
|
Infection
|
|
PF-46396 is a potent HIV-1 inhibitor with an EC50 value of 0.206 µM. PF-46396 shows antiviral activity. PF-46396 inhibits the processing of capsid (CA)/spacer peptide 1 (SP1) (p25) Gag precursor proteins and blocks maturation of the viral core particle .
|
-
-
- HY-19952R
-
|
VP 63843 (Standard); Win 63843 (Standard)
|
Reference Standards
Enterovirus
|
Infection
|
|
Pleconaril (Standard) is the analytical standard of Pleconaril. This product is intended for research and analytical applications. Pleconaril is a picornavirus capsid binding inhibitor that prevents attachment and/or virus uncoating. Pleconaril has potential for use in rhinoviruses and enteroviruses research .
|
-
-
- HY-162526
-
|
|
HIV
|
Infection
|
|
HIV capsid modulator 2 (Compound 7t) is a modulator for the HIV capsid (CA) protein. HIV capsid modulator 2 exhibits antiviral activity, which inhibits HIV-1 IIIB strain and HIV-2 ROD strain with EC50 of 0.04 and 0.13 μM. HIV capsid modulator 2 is metabolically stable in human liver microsomes .
|
-
-
- HY-174269
-
|
|
HIV
|
Infection
|
|
HIV Capsid-IN-2 (Compound IC-2b4) is a potent HIV-1 capsid protein (CA) inhibitor. HIV Capsid-IN-2 shows inhibitory effects against both HIV-1 (EC50=0.08 μM) and HIV-2. HIV Capsid-IN-2 exerts inhibitory effects during both early and late stages of infection by directly and stably binding to HIV-1 CA .
|
-
-
- HY-114956
-
|
|
HBV
|
Infection
|
|
AT-61 is a non nucleoside HBV replication inhibitor. AT-61 prevents the capsid formation of pre genomic RNA, resulting in the production of empty capsids. AT-61 has the activity of drug-resistant mutant strains. AT-61 can be used for research on hepatitis B virus infection .
|
-
-
- HY-163516
-
|
|
HBV
|
Infection
|
|
HBV-IN-45 is a selective and orally active HBV capsid assembly modulator with an IC50 of 0.51 μM for HBcAg in HBC cells. HBV-IN-45 shows potent anti-HBV activities .
|
-
-
- HY-109969
-
|
|
HBV
|
Infection
|
|
Z060228 is a capsid-targeting anti-HBV agent that inhibits HBV DNA replication in the supernatant of the HepG2.2.15 cell .
|
-
-
- HY-116633
-
|
|
Endogenous Metabolite
|
Infection
|
|
BCM-599 is a HBV (hepatitis B virus) capsid assembly inhibitor with the activity of inhibiting HBV capsid assembly. BCM-599 showed an IC50 value of 0.88μM and a CC50 value of 144μM in HepG2.2.15 cells. When used in combination with lamivudine, BCM-599 showed a synergistic inhibitory effect on viral concentration. BCM-599 can be used as an effective combined inhibition option for HBV infection .
|
-
-
- HY-W012017R
-
|
|
Reference Standards
Enterovirus
|
Infection
|
|
2-Hydroxytetradecanoic acid is a hydroxy fatty acid that inhibits cleavage between the enterovirus capsid proteins VP4 and VP2. 2-Hydroxytetradecanoic Acid has anti-virus activity .
|
-
-
- HY-142468
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-12 is potent HIV-1 inhibitor. HIV-1 inhibitor-12 inhibits HIV-1 capsid protein polymerization with an IC50 of 9 nM (WO2021104413A1, compound 1-1a) .
|
-
-
- HY-123767
-
|
|
HBV
|
Infection
|
|
HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC50 values of 0.039 µM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers .
|
-
-
- HY-177638A
-
|
|
HSV
|
Infection
|
|
ISIS 1082 sodium is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro
|
-
-
- HY-131343
-
|
|
HBV
DNA/RNA Synthesis
|
Infection
|
|
HBV-IN-4, a phthalazinone derivative, is a potent and orally active HBV DNA replication inhibitor with an IC50 of 14 nM. HBV-IN-4 induces the formation of genome-free capsids and has potent anti-HBV potencies .
|
-
-
- HY-12349
-
|
|
Enterovirus
|
Infection
|
|
H1PVAT is a potent and selective inhibitor of poliovirus serotypes (PV-1, PV-2, PV-3), and inhibits early stage of the replication. H1PVAT interacts with viral capsid directly and protects PV against heat inactivation .
|
-
-
- HY-170605
-
|
|
HBV
|
Infection
|
|
BA-AZT1 is the inhibitor for HBV polymerase and sodium taurocholate cotransporting polypeptide (NTCP). BA-AZT1 inhibits the secretion of viral capsid protein HBsAg and HBeAg with IC50 of 0.65 µM and 13.42 µM, inhibits the HBV DNA replication with an IC50 of 0.70 µM .
|
-
-
- HY-146011
-
|
|
HBV
DNA/RNA Synthesis
|
Infection
|
|
HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM) .
|
-
-
- HY-149357
-
|
|
HBV
|
Infection
|
|
Yhhu6669 is an anti-HBV agent. Yhhu6669 inhibits HBV DNA. Yhhu6669 inhibits HBV replication by inducing the formation of DNA-free capsids. Yhhu6669 decreases HBV DNA and HBcAg in AAV/HBV-infected mice. Yhhu6669 has favorable PK properties .
|
-
- HY-144714
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-18 (compound II-13c) is a potent HIV-1 capsid inhibitor with an EC50 value of 5.14 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >9.51) .
|
-
- HY-144715
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-18 (compound V-25i) is a potent HIV-1 capsid inhibitor with an EC50 value of 2.57 μM for HIV-1 NL4-3. HIV-1 inhibitor-18 has certain cytotoxicity (MT-4 cells CC50 >8.55) .
|
-
- HY-163999
-
|
|
TMV
|
Infection
|
|
TMV-IN-12 (compound 4) is an inhibitor of tobacco mosaic virus (TMV) with antifungal properties. TMV-IN-12 effectively prevents TMV particle aggregation and self-assembly of TMV capsid protein (TMV-CP) (Kd=0.142 μM), preventing TMV from infecting tobacco plants .
|
-
- HY-B1464R
-
|
|
Reference Standards
Bacterial
HBV
|
Infection
Inflammation/Immunology
|
|
Cetylpyridinium (chloride) (Standard) is the analytical standard of Cetylpyridinium (chloride). This product is intended for research and analytical applications. Cetylpyridinium chloride, a cationic quaternary ammonium compound, is an anti-bacterial agent with broad-spectrum activity. Cetylpyridinium chloride is an effective anti-HBV capsid assembly inhibitor with an IC50 of 2.5 μM. Cetylpyridinium chloride is used in pesticides and various types of mouthwashes, and other personal care products .
|
-
- HY-168923
-
|
|
Enterovirus
|
Infection
|
|
HR-568 exhibits broad-spectrum anti-enterovirus activity. HR-568 inhibits enterovirus species EV-A71, E30 and CVA24 in cell MRC-5 with EC50 of 1.53 μM, 0.4 μM and 1.22 μM. HR-568 targets hydrophobic canyon pocket on the enterovirus capsid protein, and inhibits the virus replication .
|
-
- HY-104074S
-
|
SCH-48973-d3; V-073-d3
|
Isotope-Labeled Compounds
Enterovirus
|
Others
|
|
Pocapavir-d3 (SCH-48973-d3; V-073-d3) is the deuterium labeled Pocapavir (HY-104074) . Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
|
-
- HY-116113
-
|
|
HIV
DNA/RNA Synthesis
|
Infection
|
|
SJP-L-5 is an HIV-1 capsid dissociation inhibitor. SJP-L-5 exhibits inhibitory activity against multiple HIV-1 strains, with an EC50 ranging from 0.16 to 0.97 μg/mL. SJP-L-5 inhibits viral infection by blocking HIV-1 viral DNA entry into the nucleus. SJP-L-5 can be used in HIV-1 infection research .
|
-
- HY-P10653
-
|
|
HCV
HIV
|
Infection
|
|
C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the HIV virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .
|
-
- HY-124364
-
|
|
HBV
Cytochrome P450
|
Infection
Metabolic Disease
|
|
RO6889678 is a highly potent HBV capsid formation inhibitor with a complex absorption, distribution, metabolism, and excretion (ADME) profile. RO6889678 is a potent inducer of CYP3A4 and coregulated proteins in human hepatocytes. RO6889678 is metabolized by a combination of CYP3A4-mediated oxidation and UDP-glucuronosyltransferase UGT1A3- and UGT1A1-mediated direct glucuronidation .
|
-
- HY-P4292
-
|
|
HIV
Amino Acid Derivatives
|
Infection
|
|
H-Gly-Pro-Gly-NH2 is a tripeptide that inhibits HIV-1 replication. H-Gly-Pro-Gly-NH2 inhibits the activity of HIV-1 IIIB and HIV-2 ROD with EC50 values of 35 µM and 30 µM, respectively. H-Gly Pro Gly NH2 inhibits HIV-1 replication in vitro by interfering with capsid formation. H-Gly Pro Gly NH2 has antiviral activity and can be used for virus research .
|
-
- HY-N0842R
-
|
PA-457 (Standard); MPC-4326 (Standard); YK FH312 (Standard)
|
Reference Standards
Virus Protease
|
Infection
|
|
Bevirimat (Standard) is the analytical standard of Bevirimat. This product is intended for research and analytical applications. Bevirimat (PA-457, MPC-4326, YK FH312) is an inhibitor of HIV-1 viral particle maturation.Bevirimat specifically inhibits the final rate-limiting step in Gag processing, preventing the release of the mature capsid protein (CA) from its precursor (CA-SP1), resulting in the production of immature non-infectious viral particles. Bevirimat can be used in HIV-1 infection studies[1][2][3][4].
|
-
- HY-176224
-
|
|
Bacterial
|
Infection
Inflammation/Immunology
|
|
Anti-virulence factor-IN-2 (compound C7) is an inhibitor targeting the virulence factor KpsM in Escherichia coli. kpsM mediates the translocation of capsular polysaccharides to the cell surface, allowing kpsM-positive E. coli to escape the phagocytosis of the scavenger receptor Marco on liver Kupffer cells, leading to bacterial dissemination. kpsM-positive E. coli exacerbates ethanol-induced liver disease. Anti-virulence factor-IN-2 can inhibit the ethanol-induced liver disease model caused by kpsM-dependent capsid in mice and has anti-infective activity. Anti-virulence factor-IN-2 can be used for the study of alcoholic hepatitis .
|
-
- HY-173121
-
|
|
HBV
|
Infection
|
|
KR019 is a potent HBV capsid assembly modulator, exhibits potent antiviral activity in HBV-replicating cells. KR019 binds to the hydrophobic pocket at the core protein dimer-dimer interface, misdirecting capsid assembly into genome-free capsids and thereby inhibiting viral replication .
|
-
- HY-183260
-
|
|
HBV
Cytochrome P450
|
Infection
|
|
HBV-IN-57 is an orally active HBV inhibitor with pan-genotypic efficacy against HBV genotypes B/C. HBV-IN-57 inhibits HBV DNA replication and HBV capsid assembly. HBV-IN-57 can be used for the research of chronic hepatitis B .
|
-
- HY-104074R
-
|
SCH-48973 (Standard); V-073 (Standard)
|
Reference Standards
Enterovirus
|
Infection
|
|
Pocapavir (Standard) is the analytical standard of Pocapavir (HY-104074). This product is intended for research and analytical applications. Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
|
-
- HY-103078R
-
|
|
Reference Standards
HIV
Reverse Transcriptase
|
Infection
|
|
I-XW-053 (Standard) is the analytical standard of I-XW-053 (HY-103078). This product is intended for research and analytical applications. I-XW-053 is a specific anti-HIV-1 capsid inhibitor (IC50=164.2 μM). By binding to the CA NTD-NTD hexamerization interface and the R173 region of CTD (Kd=66.3 μM), I-XW-053 disrupts capsid function and reduces polymerization levels. I-XW-053 effectively blocks HIV-1 uncoating, inhibits reverse transcription and early replication, and exhibits broad-spectrum activity against primary HIV-1 isolates in peripheral blood mononuclear cells. I-XW-053 can be widely used in studies related to HIV-1 infection .
|
-
- HY-165513
-
|
|
HIV
|
Infection
|
|
Niruriside is a HIV REV/RRE complex inhibitor. Niruriside specifically inhibits the binding interaction between HIV REV protein and RRE RNA, with an IC50 of 3.3 μM, and shows no significant activity against the unrelated R17 capsid protein/operator RNA binding system. At the tested concentrations, Niruriside fails to protect CEM-SS cells from acute HIV-1 infection. Niruriside can be used in the research of human immunodeficiency virus (HIV) infection .
|
-
- HY-176531
-
|
|
Others
|
Infection
|
|
Antiviral agent 69 (Compound L2) is a capsid protein residue THR155-targeting inhibitor of phytoviral intercellular traffic. Antiviral agent 69 has an excellent antiviral activity against Potato virus Y (PVY) with an EC50 of 128.10 μg/mL for inactivation effect. Antiviral agent 69 effectively decreases viral accumulation in host plant Nicotiana benthamiana, promising for novel pesticide research and development .
|
-
- HY-183322
-
|
|
HPV
|
Infection
|
|
Antiviral agent 83 is a boronic acid-modified Neocryptolepine (HY-E70250) derivative and is an anti-HPV agent. Antiviral agent 83 bind to the viral capsid protein and/or envelope protein, inducing conformational changes that effectively obstruct the interaction between the virus and host cell receptors. Antiviral agent 83 exhibits inhibitory activity against multiple high-risk HPV strains. Antiviral agent 83 inhibits HPV infection in vitro and in vaginal tract in vivo .
|
-
- HY-182924
-
|
|
PROTACs
Enterovirus
|
Infection
|
|
Jun15702 is a PROTAC degrader targeting the capsid protein VP1 of enterovirus D68. Jun15702 recruits the Cereblon (CRBN) E3 ligase and activates the ubiquitin-proteasome pathway. Jun15702 inhibits viral entry and exerts inhibitory effects during the early, middle and late stages of viral replication. Jun15702 exhibits antiviral activity against multiple wild-type enterovirus D68 strains, and also shows submicromolar antiviral activity against the Pleconaril (HY-19952)-resistant enterovirus D68 variant rMO-VP1 F159V. Jun15702 can be used in studies related to enterovirus D68 (EV-D68) infection .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-125474
-
|
|
Biochemical Assay Reagents
|
|
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P10805
-
|
|
HIV
|
Infection
|
|
Capsid assembly inhibitor is a 12-mer peptide that binds the capsid (CA) domain of Gag and inhibits assembly of immature- and mature-like HIV-1 capsid particles in vitro .
|
-
- HY-P10653
-
|
|
HCV
HIV
|
Infection
|
|
C5A is a microbicidal peptide, anti-hepatitis C virus (HCV), and anti-HIV agent. C5A disrupts the membrane integrity of the HIV virion as well as the integrity of the conical capsid core that surrounds the viral genome. C5A inhibits in vitro infectivity of a broad range of primary HIV isolates in various primary target cells. C5A protects mice against vaginal and rectal HIV challenges .
|
-
- HY-P4292
-
|
|
HIV
Amino Acid Derivatives
|
Infection
|
|
H-Gly-Pro-Gly-NH2 is a tripeptide that inhibits HIV-1 replication. H-Gly-Pro-Gly-NH2 inhibits the activity of HIV-1 IIIB and HIV-2 ROD with EC50 values of 35 µM and 30 µM, respectively. H-Gly Pro Gly NH2 inhibits HIV-1 replication in vitro by interfering with capsid formation. H-Gly Pro Gly NH2 has antiviral activity and can be used for virus research .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-104074S
-
|
|
|
Pocapavir-d3 (SCH-48973-d3; V-073-d3) is the deuterium labeled Pocapavir (HY-104074) . Pocapavir (SCH-48973) is an orally active capsid inhibitor. Pocapavir prevents virion uncoating upon entry into the cell. Pocapavir has antiviral activity against polioviruses. Pocapavir also inhibits enterovirus infections .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-19476
-
|
|
|
Alkynes
|
|
AG-7404 is an orally active, irreversible inhibitor of the picornavirus 3C protease. AG-7404 blocks the processing of viral polyproteins, thereby inhibiting viral replication. AG-7404 has synergistic antiviral activity with capsid inhibitors such as V-073 (HY-104074) or BTA798 (HY-106254) and is effective against V-073-resistant variants. AG-7404 is used in the study of enterovirus infections such as poliovirus .
|
-
- HY-124614
-
GLP-26
2 Publications Verification
|
|
Alkynes
|
|
GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC50=3 nM), and reduces cccDNA by >90% at 1 μM.
GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools . GLP-26 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
| Cat. No. |
Product Name |
|
Classification |
-
- HY-177638
-
|
|
|
Antisense Oligonucleotides
|
|
ISIS 1082 is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro
|
-
- HY-177638A
-
|
|
|
Antisense Oligonucleotides
|
|
ISIS 1082 sodium is an antisense oligonucleotide targeted to the translation initiation codon of herpes simplex virus (HSV) type 1 and 2 virion capsid protein. It has been shown to inhibit HSV-1 replication in vitro
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: